```
GSE22886_NAIVE_BCELL_VS_BM_PLASMA_CELL_UP, GSE22886_NAIVE_BCELL_VS_BM_PLASMA_CELL_UP
                                                                                                                                                                     GSE25146_UNSTIM_VS_HELIOBACTER_PYLORI_LPS_STIM_AGS_CELL_DN, GSE25146_UNSTIM_VS_HELIOBACTER_PYLORI_LPS_STIM_AGS_CELL_DN
                                                                                                                                                                     / GSE15330_HSC_VS_PRO_BCELL_UP, GSE15330_HSC_VS_PRO_BCELL_UP
                                                                                                                                                                     GSE13411 NAIVE BCELL VS PLASMA CELL UP, GSE13411 NAIVE BCELL VS PLASMA CELL UP
                                                                                                                                                                     / GSE5455_EX_VIVO_VS_POST_24H_INCUBATION_MONOCYTES_FROM_TUMOR_BEARING_MOUSE_DN, GSE5455_EX_VIVO_VS_POST_24H_INCUBATION_MONOCYTES_FROM_TUMOR_BEARING_MOUSE_DN
                                                                                                                                                                     SE5679_PPARG_LIGAND_ROSIGLITAZONE_VS_ROSIGLITAZONE_AND_RARA_AGONIST_AM580_TREATED_DC_DN, GSE5679_PPARG_LIGAND_ROSIGLITAZONE_VS_ROSIGLITAZONE_AND_RARA_AGONIST_AM580_TREATED_DC_DN
                                                                                                                                                                     - GSE3982 EOSINOPHIL VS DC UP, GSE3982 EOSINOPHIL VS DC UP
ELL VS MEMORY BCELL DN, GSE12366 PLASMA CELL VS MEMORY BCELL DN 🕻
                                                                                                                                                                     GSE3203_UNTREATED_VS_IFNB_TREATED_LN_BCELL_UP, GSE3203_UNTREATED_VS_IFNB_TREATED_LN_BCELL_UP
                                                                                                                                                                       GSE39820_IL1B_IL6_VS_IL1B_IL6_IL23A_TREATED_CD4_TCELL_UP, GSE39820_IL1B_IL6_VS_IL1B_IL6_IL23A_TREATED_CD4_TCELL_UP
                                                                                                                                                                      `SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_MEDIUM_HIGH_ADVERSE_EVENT_SUBJECTS_1DY_UP, SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_MEDIUM_HIGH_ADVERSE_EVENT_SUBJECTS_1DY_UP
                                                                                                                                                                     GSE29164 DAY3 VS DAY7 UNTREATED MELANOMA UP, GSE29164 DAY3 VS DAY7 UNTREATED MELANOMA UP
                                                                                                                                                                      SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_HIGH_VS_LOW_RESPONDERS_MEDIUM_HIGH_ADVERSE_EVENTS_SCORE_1DY_CORRELATED_WITH_TRANSITIONAL_B_CELLS_UP, SOBOLEV_PBMC_PANDEMRIX_SCORE_1DY_CORRELATED_WITH_TRANSITIONAL_B_CELLS_UP, SOBOLEV_PBMC_PANDEMRIX_SCORE_1DY_CORRELATED_WITH_TRANSITIONAL_B_CELLS_UP, SOBOLEV_PBMC_PANDEMRIX_SCORE_1DY_TRANSITIONAL_B_TRANSITIONAL_B_TRANSITIONAL_B_TRANSITIONAL_B_TRANSITIONAL_B_TRANSITIONAL_B_TRANSITIONAL_B_TRANSITIONAL_B_TRANSITIONAL_B_TRANSITIONAL_B_TRANSITIONAL_B_TRANSITIONAL_B_TRANSITIONAL_B_TRANSITIONAL_B_TRANSITIONAL_B_TRANSITI
                                                                                                                                                                       VOIGT PBMC FLUARIX AGE 50 74YO FEMALES VS MALES 0DY TO 28D UP, VOIGT PBMC FLUARIX AGE 50 74YO FEMALES VS MALES 0DY TO 28D UP
                                                                                                                                                                      WEINBERGER_BLOOD_TWINRIX_AGE_20_40_AND_60_84YO_CORRELATED_WITH_HIGH_ANTI_HBS_CONC_AT_WEEK_4_POST_BOOSTER_VACC_1DY_POSITIVE, WEINBERGER_BLOOD_TWINRIX_AGE_20_40_AND_60_84YO_CORRELATED_WITH_HIGH_ANTI_HBS_CONC_AT_WEEK_4_POST_BOOSTER_VACC_1DY_POSITIVE
```